Sexual Health In Vitro Research Only

PT-141 (Bremelanotide): FDA-Approved Central Arousal Mechanism Research

FDA Approved 2019 — Vyleesi for HSDD

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin agonist and FDA-approved drug (Vyleesi, June 2019) for Hypoactive Sexual Desire Disorder in premenopausal women. Unlike PDE5 inhibitors (Viagra, Cialis) which act peripherally on blood vessels, PT-141 activates MC3R and MC4R receptors in the hypothalamus — directly stimulating central dopaminergic arousal pathways. In the RECONNECT Phase III trial (Portman et al. 2019), it produced statistically significant improvements in desire and distress scores versus placebo.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

🧠

MC3R & MC4R Hypothalamic Activation

Activates melanocortin 3 and 4 receptors in the hypothalamus and limbic system — directly stimulating central arousal pathways, not peripheral vascular mechanisms.

⚗️

Mesolimbic Dopamine Release

MC4R activation in the mesolimbic pathway triggers dopamine release, increasing sexual motivation, desire, and reward anticipation through CNS mechanisms.

🔬

Testosterone-Independent Activation

Activates desire pathways independent of sex hormone status — effective in subjects where hormonal treatments have failed or are contraindicated.

💡

Central vs. Peripheral Distinction

Works when PDE5 inhibitors fail (particularly in psychogenic or desire-deficit dysfunction) because it targets central brain arousal circuits rather than penile vasculature.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

💊

FDA

Regulatory Approval

Vyleesi — Hypoactive Sexual Desire Disorder

📊

68%

Erectile Response Rate

Sildenafil-failed subjects (Shadiack 2007)

🔬

Phase III

Human Trial Data

RECONNECT study — Portman 2019

🧠

CNS

Mechanism Location

Hypothalamus — not peripheral

PT-141 vs. Placebo — Erectile Response in Sildenafil Non-Responders

PT-141 Responders

Placebo Response

Non-Responders

Source: Shadiack et al. (2007) Int J Impot Res. PMID 17301796. Men with ED who had previously failed sildenafil.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

78%

Tolerability

Medium Severity

40%

Nausea Incidence

Medium Severity

22%

Flushing

Low Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.